2 edition of Interferon-based therapies for chronic hepatitis C virus infection found in the catalog.
Interferon-based therapies for chronic hepatitis C virus infection
Donald Robert Husereau
by Canadian Coordinating Office for Health Technology Assessment in Ottawa
Written in English
|Statement||Donald Husereau, Ken Bassett, Ronald Koretz.|
|Series||Technology report -- issue 47, Technology report (Canadian Coordinating Office for Health Technology Assessment) -- issue 47.|
|Contributions||Bassett, Kenneth, 1952-, Koretz, Ronald L., Canadian Coordinating Office for Health Technology Assessment|
|The Physical Object|
|Pagination||vi, 52 p.|
|Number of Pages||52|
For over a decade, the vast majority of new hepatitis C virus (HCV) infections have been among young people who inject drugs (PWID). Well-characterized gaps in chronic HCV diagnosis, evaluation, and treatment have resulted in fewer than 5% of PWID receiving HCV treatment. While interferon-based . Modeling identifies chronic hepatitis C patients who were cured with a reduced duration of direct-acting antivirals (DAA). • Duration of DAA treatment has not been previously modeled in persons with recent (hepatitis C infection.
Hepatitis C virus (HCV) infection is a leading cause of cirrhosis and hepatocellular carcinoma, globally. Most individuals infected with HCV are asymptomatic. The introduction of the newer direct-acting antiviral (DAA) therapies has led to achievement of treatment success rates of more than 90%. Sus . Chronic hepatitis C virus (HCV) infection is an infection that affects over 71 million people worldwide that primarily leads to significant morbidity and mortality through its predisposition to liver fibrosis, cirrhosis, and liver cancer. In addition, extrahepatic manifestations, such as mixed cryog .
Chronic hepatitis C affects million Americans and is the major cause of cirrhosis, end-stage liver disease, and hepatocellular carcinoma in the United States . The current recommended therapy for chronic hepatitis C is a combination of peginterferon and ribavirin given for 24 or 48 weeks, depending on the viral genotype . Oral erosive lichen planus with epidermolytic hyperkeratosis during interferon alfa-2b therapy for chronic hepatitis C virus infection. J Am Acad Dermatol. Jun. 36(6 Pt 1) Gupta G, Holmes SC, Spence E, Mills PR. Capillaritis associated with interferon-alfa treatment of chronic hepatitis C infection.
Northern editorials on secession.
Nuclear forces and the few-nucleon problem
The story of Fuqua Industries, inc.
Reaching the needs of people with visual disabilities
North Bay anti-drug focus community coalition
Insurrection in Poshansk.
The Christmas Activity Book
The nature of human movement
A-Z of Cars of the 1930s (A-Z)
management of tropical moist forest lands
Lost mosaics and frescoes of Rome of the mediaeval period
A discourse, shewing, that the real first cause of the straits and difficulties of this province of Massachusetts Bay, is its extravagancy, & not paper money
education (Northern Ireland) order 1984.
Introduction. Hepatitis C virus (HCV) is the most common cause of chronic hepatitis, which leads to severe complications over time.1 In the mid’s, it was shown that most post-transfusion cases of hepatitis were neither due to hepatitis A nor B virus, the only known hepatitis viruses at the time.
Hence, it was referred to as the “non-A non-B hepatitis” until its discovery in Cited by: 3. Askarieh G, Alsio A, Pugnale P, et al. Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C Virus RNA and overall viral response to therapy in chronic hepatitis C.
Hepatology. ; –Cited by: Dear Editor, We greatly enjoyed reading the excellent meta-analysis by Alavian and colleagues on the efficacy and safety of peginterferon (PEG-IFN) alpha-1a vs. 2b for the treatment of chronic hepatitis C virus (HCV) immune effects of interferons, often in combination with other drugs, have been utilized to treat several diseases, such as HCV and HCV-related autoimmune diseases.
Sinceinterferon-alfa (IFN-α) monotherapy has been administered for patients with chronic hepatitis C (CHC).However, sustained response rate is only about 8% to 9%. Subsequent introduction of ribavirin in combination with IFN-α was a major breakthrough in the treatment of ned virological responses (SVRs) rate is about 30% in hepatitis C virus genotype 1 (HCV-1) patients, and.
Introduction. Chronic hepatitis C virus (HCV) infection has caused an epidemic with approximately million people infected worldwide and three to four million people newly infected each year. 1, 2 The majority of newly infected individuals develop chronic infection.
Natural history studies show that 5% to 20% of patients develop cirrhosis after about 20 years of infection. 3 An Cited by: Benefits. Treatment of all patients has the potential to prevent more liver-related morbidity.
A systematic review with meta-analysis and meta-regression estimated that the prevalence of cirrhosis at 20 years after the initial infection was 16% (14–19%) for all studies, ranging from 7% (4–12%) to 18% (16–21%) according to the types of studies and recruitment of individuals ().
Chronic Hepatitis C Virus: Lessons from the Past, Promise for the Future documents the monumental advances that have been made in our understanding of chronic HCV during the past decade.
The first section reviews the natural history of chronic HCV, how this virus can affect other organs in addition to the liver, and whether treating chronic HCV alters the natural history of this disease. Be aware that the only treatment proven through controlled clinical trials to show sustained clearance of the hepatitis C virus (as detected by HCV RNA testing of the blood) is a combination of direct acting antivirals (DAA’s) with or without an interferon-based antiviral therapy some therapies have achieved a 90 – % cure rate.
Chronic Hepatitis C virus (HCV) infection carries a significant clinical burden in the United States, affecting more than million Americans. Untreated chronic HCV infection can result in cirrhosis, portal hypertension, and hepatocellular carcinoma.
Previous interferon based treatment carried low rates of success and significant adverse effects. Introduction. Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death in the world.
1 Viral eradication after interferon (IFN)-based therapy has been associated with a reduced risk of developing HCC, in chronic hepatitis C (CHC) patients. With the development of potent direct-acting antiviral agent (DAA) combinations, an over 90% sustained virological response.
AASLD practice guideline on treatment of genotype 1 chronic hepatitis C infection ( Hepatology Oct;54(4)), commentary can be found in Hepatology Mar;55(3); AASLD/IDSA recommendations for testing, managing, and treating hepatitis C (AASLD/IDSA May 24).
Introduction: Hepatitis C virus (HCV) infects nearly million people worldwide and is a leading cause of progressive liver damage, cirrhosis, and hepatocellular carcinoma.
Curative therapies have historically relied on interferon-based treatments and were limited by significant toxicity and poor response rates, particularly among patients with prior treatment failure and advanced hepatic. New research has highlighted means to individualize treatment for chronic infection with hepatitis C virus, and new medications offer promise to improve treatment of hepatitis C.
The current article reviews recent findings in the treatment of chronic infection with hepatitis C virus and highlights future directions for treatment.
Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, Janczewska E, Villamil F, Scott J, Peeters M, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet. Key Points. Question Is interferon-based antiviral therapy associated with Parkinson disease incidence in patients with chronic hepatitis C virus infection?. Findings In this cohort study of patients with hepatitis C virus infection, the group treated with antiviral therapy had lower incidence density and risk of developing PD compared with the untreated group.
The goal of treatment is to have no hepatitis C virus detected in your body at least 12 weeks after you complete treatment. Researchers have recently made significant advances in treatment for hepatitis C using new, "direct-acting" antiviral medications, sometimes in combination with existing ones.
In the Study of Viral Resistance to Antiviral Therapy of Hepatitis C (Virahep-C), a multicenter trial comparing the rates of response to peginterferon and ribavirin among white and African American patients with chronic genotype 1 infection, only 28% of African American patients attained SVR, compared with 52% of white patients .
However, current therapies are genotype-specific and have variable efficacy amongst less prevalent HCV variants. Areas covered: This review covers the preclinical and clinical development of sofosbuvir/velpatasvir (SOF/VEL), an interferon-free, once daily, pangenotypic treatment for the treatment of chronic hepatitis C virus (HCV) infection.
Association of Antiviral Therapy With Risk of Parkinson Disease in Patients With Chronic Hepatitis C Virus Infection. Evidence suggested that the PD incidence was lower in patients with chronic HCV infection who received interferon-based antiviral therapy; this finding may support the hypothesis that HCV could be a risk factor for PD.
Introduction. An estimated million Americans, including more thanVeterans, are chronically infected with hepatitis C virus (HCV) who do not clear the virus go on to develop a chronic infection with widely varying course, influenced by host, viral, and environmental factors e improved treatments for HCV, ongoing and apparent large increases in the.
Chronic Hepatitis C Virus: Lessons from the Past, Promise for the Future documents the monumental advances that have been made in our understanding of chronic HCV during the past decade. The first section reviews the natural history of chronic HCV, how this virus can affect other organs in addition to the liver, and whether treating chronic HCV alters the natural history of this cturer: Springer.Hepatitis C viral infection (HCV) is one type of hepatitis.
According to the CDC, in there were an estima cases of acute hepatitis C infections in the US. An estimated million people in the US have chronic hepatitis C. The virus is spread from person-to-person via blood-to-blood contact.Chronic Hepatitis C Virus: Advances in Treatment, Promise for the Future documents the monumental advances that have been made in our understanding of chronic HCV during the past decade.
The first section reviews the natural history of chronic HCV, how this virus can affect other organs in addition to the liver, and whether treating chronic HCV alters the natural history of this disease.